Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

69
Gilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug

2018-07-17 seekingalpha
Gilead (GILD) has annual revenues in the HIV class of drugs of over $14.2 billion, and only has one phase 3 drug in clinical trials to protect its dominance in this category. GILD’s $14 billion annual income stream could be in jeopardy, because they are literally one drug approval away from an armageddon they admit in their 10-K is coming. A small competitor, Cytodyn Inc. (OTCQB:CYDY), has been struggling for over a decade to get PRO 140 approved as a salvage therapy to drug resistant HIV patients.
CYDY AMGN GILD JNJ GSK KITE PFE GSK PGNX

55
FDA Action Alerts: Lannett, Indivior, Insys and Progenics

2018-07-16 biospace
July can be a notoriously slow period for U.S. Food and Drug Administration (FDA) activity, and this year is no different. There are only five PDUFA dates scheduled for the month, and the first one was a supplemental approval for Merck’s Keytruda for adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy.
DRRX PGNX

50
PGNX / Progenics Pharmaceuticals, Inc. / FEDERATED INVESTORS INC /PA/ - null (Passive Investment)

2018-07-10 sec.gov
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PGNX

50
PGNX / Progenics Pharmaceuticals, Inc. / FEDERATED INVESTORS INC /PA/ - null (Passive Investment)

2018-07-10 sec.gov
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PGNX

86
Major Biopharma Catalysts on July’s FDA Calendar

2018-07-07 247wallst
Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be massive upside.
CBIO TBPH NBIX GSK ZYNE ABBV GSK ABBV DRRX PGNX

85
XON / Intrexon Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-07 fintel.io
Intrexon Corp. (NYSE:XON) has 183 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 111,162,559 shares. Largest shareholders include Third Security, LLC, Iridian Asset Management Llc/ct, Vanguard Group Inc, FMR LLC / Fidelity, Lmm Llc, State Street Corp, First Trust Advisors Lp, Morgan Stanley, BlackRock Inc.
STT STT.PRC XON STT.PRE STT.PRD STT.PRG MS.PRE VRX MS.PRF MS.PRG ISRG MS.PRA PGNX BLK MS.PRI BSX MS.PRK ICUI MS SLXP MZOR

52
OCIP / OCI Partners LP - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-07 fintel.io
OCI Partners LP (NYSE:OCIP) has 22 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 76,725,550 shares. Largest shareholders include Oci N.v., Morgan Stanley, Cowen Group, Inc., UBS Group AG, PCJ Investment Counsel Ltd., Bard Associates Inc, Credit Capital Investments LLC, Quinn Opportunity Partners LLC, Deutsche Bank Ag\, and Renaissance Technologies LLC.
COWNL DB MS.PRE VRX MS.PRF MS.PRG MS.PRA OCIP PGNX COWN MS.PRI UBS MS.PRK UBS.PRDCL MS SLXP CWGRP ULSGF

49
AUTL / Autolus Therapeutics plc - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-07 fintel.io
Autolus Therapeutics plc (NASDAQ:AUTL) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Autolus Therapeutics plc (NASDAQ:AUTL) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
VRX AUTL SLXP PGNX

52
TCDA / Tricida, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-06 fintel.io
Tricida, Inc. (NASDAQ:TCDA) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Tricida, Inc. (NASDAQ:TCDA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
TCDA VRX SLXP PGNX

49
XSPA / XpresSpa Group, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-06 fintel.io
XpresSpa Group, Inc. (NASDAQ:XSPA) has 27 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 6,308,828 shares. Largest shareholders include AWM Investment Company, Inc., Alyeska Investment Group, L.P., Perritt Capital Management Inc, Vanguard Group Inc, BlackRock Inc., Oberweis Asset Management Inc/, Geode Capital Management, Llc, California Public Employees Retirement System, Renaissance Technologies LLC, and Boardman Bay Capital Management Llc.
BLK VRX SLXP PGNX XSPA

50
WYY / WidePoint Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-06 fintel.io
WidePoint Corp. (AMEX:WYY) has 31 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 19,655,555 shares. Largest shareholders include Nokomis Capital, L.L.C., Vanguard Group Inc, First Wilshire Securities Management Inc, Raymond James Financial Services Advisors, Inc., Perritt Capital Management Inc, King Luther Capital Management Corp, Geode Capital Management, Llc, Intellectus Partners, LLC, Renaissance Technologies LLC, and B.
VRX WYY SLXP PGNX

49
XPLR / Xplore Technologies Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-05 fintel.io
Xplore Technologies Corp. (NASDAQ:XPLR) has 41 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,969,856 shares. Largest shareholders include Phoenix Venture Fund LLC, Merriman Wealth Management, LLC, Royal Bank Of Canada, Vanguard Group Inc, Renaissance Technologies LLC, AWM Investment Company, Inc.
XPLR RY RY VRX RY.PRSCL RY.PRS ZBRA RBCDF SLXP RY.PRT PGNX

49
RDGL / Vivos Inc - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-05 fintel.io
Vivos Inc (OTC:RDGL) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Vivos Inc (OTC:RDGL) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
RDGL VRX SLXP PGNX

50
JOEZ / Joe's Jeans Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-05 fintel.io
Joe's Jeans Inc. (NASDAQ:JOEZ) has 14 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 564,008 shares. Largest shareholders include Vanguard Group Inc, GM Advisory Group, Inc., Renaissance Technologies LLC, RGT Capital Management, Ltd., Geode Capital Management, Llc, Altfest L J & Co Inc, BlackRock Inc.
BLK JOEZ VRX SLXP PGNX

52
EYPT / EyePoint Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-05 fintel.io
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has 2 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 228,928 shares. Largest shareholders include Panagora Asset Management Inc, and Bridgeway Capital Management Inc. EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.
EYPT VRX RYTM SLXP PGNX

PGNX: Progenics Pharmaceuticals Analysis and Research Report

2018-07-02 - Asif

Business Overview The company develop innovative medicines and other technologies to target and treat cancer. The company's pipeline includes: (1) therapeutic agents designed to precisely target cancer (AZEDRA, 1095, and PSMA TTC); (2) prostate-specific membrane antigen (“PSMA”) targeted imaging agents for prostate cancer (1404 and PyLTM); and (3) imaging analysis technology. The company's first commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Salix Pharmaceuticals, Inc. (a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”)). On October 31, 2017, the company completed the rolling submission of its NDA for AZEDRA. The FDA has accepted its NDA for review, granted its request for Priority Review, and set an initial action date of April 30, 2018 under the PDUFA, which was extended in March by three months to July 30, 2018. Progenics Pharmaceuticals is developing AZEDRA as a treatment for pa...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to PGNX / Progenics Pharmaceuticals, Inc. on message board site Silicon Investor.

progenics
CUSIP: 743187106